Influenza virus and Epstein-Barr virus peptides
| CEF product | Peptide sequence | Catalog no. | Quantity | GBP |
| CEF1, Influenza Matrix Protein M1 (58 – 66) | GILGFVFTL | AB-CEF001 | 1 mg | £105 |
| CEF2, Influenza Virus PA (46 – 54) | FMYSDFHFI | AB-CEF002 | 1 mg | £105 |
| CEF3, Influenza Virus M1 (13 – 21) | SIIPSGPLK | AB-CEF003 | 1 mg | £105 |
| CEF4, Influenza Virus NP (342 – 351) | RVLSFIKGTK | AB-CEF004 | 1 mg | £105 |
| CEF5, Influenza Virus NP (91 – 99) | KTGGPIYKR | AB-CEF005 | 1 mg | £105 |
| CEF6, Influenza Virus NP | LPFDKTTVM | AB-CEF006 | 1 mg | £105 |
| CEF7, Influenza Virus NP (380 – 388) | ELRSRYWAI | AB-CEF007 | 1 mg | £105 |
| CEF8, Influenza Virus NP (383 – 391) | SRYWAIRTR | AB-CEF008 | 1 mg | £105 |
| CEF9, Influenza Virus M1 128 – 135 | ASCMGLIY | AB-CEF009 | 1 mg | £105 |
| CEF10, Epstein – Barr Virus LMP2 (426 – 434) | CLGGLLTMV | AB-CEF010 | 1 mg | £105 |
| CEF11, Epstein – Barr Virus BMLF1 (280 – 288) | GLCTLVAML | AB-CEF011 | 1 mg | £105 |
| CEF12, Epstein – Barr Virus latent NA3B (399 – 408), AVF | AVFDRKSDAK | AB-CEF012 | 1 mg | £105 |
| CEF14, Epstein – Barr Virus RTA Protein (28 – 37) | DYCNVLNKEF | AB-CEF014 | 1 mg | £105 |
| CEF15, Epstein – Barr Virus Lytic Cycle Protein BZLF – 1(190 – 197) | RAKFKQLL | AB-CEF015 | 1 mg | £105 |
| CEF16, Epstein – Barr Virus latent NA – 3A (337 – 347) | FLRGRAYGL | AB-CEF016 | 1 mg | £105 |
| CEF17, Epstein – Barr Virus latent NA – 3A (158 – 166) | QAKWRLQTL | AB-CEF017 | 1 mg | £105 |
| CEF18, Epstein – Barr Virus latent NA – 3C (258 – 266) | RRIYDLIEL | AB-CEF018 | 1 mg | £105 |
| CEF19, Epstein – Barr Virus latent NA – 3A (458 – 466) | YPLHEQHGM | AB-CEF019 | 1 mg | £105 |
| CEF20, Cytomegalovirus, CMV pp65 (495 – 503) | NLVPMVATV | AB-CEF020 | 1 mg | £105 |
| CEF21, Cytomegalovirus, CMV pp65 (417 – 426) | TPRVTGGGAM | AB-CEF021 | 1 mg | £105 |
| CEF22, Cytomegalovirus, CMV pp65 (378 – 389) | SDEEEAIVAYTL | AB-CEF022 | 1 mg | £105 |
| CEF23, Cytomegalovirus, CMV pp65 (123 – 131) | IPSINVHHY | AB-CEF023 | 1 mg | £105 |
| CEF24, Influenza Virus PB1 Peptide (591 – 599) | VSDGGPNLY | AB-CEF024 | 1 mg | £105 |
| CEF25, Influenza Virus NP (44 – 52) | CTELKLSDY | AB-CEF025 | 1 mg | £105 |
| CEF26, Influenza Virus NP (265 – 274) | ILRGSVAHK | AB-CEF026 | 1 mg | £105 |
| CEF27, Epstein – Barr Virus BRLF – 1 lytic (148 – 156) | RVRAYTYSK | AB-CEF027 | 1 mg | £105 |
| CEF28, Epstein – Barr Virus latent NA – 3A (603 – 611) | RLRAEAQVK | AB-CEF028 | 1 mg | £105 |
| CEF29, Epstein – Barr Virus latent NA – 3B (416 – 424) | IVTDFSVIK | AB-CEF029 | 1 mg | £105 |
| CEF30, Epstein – Barr Virus BRLF1 (134 – 142) | ATIGTAMYK | AB-CEF030 | 1 mg | £105 |
| CEF31, Epstein – Barr Virus latent NA – 3A (379 – 387) | RPPIFIRRL | AB-CEF031 | 1 mg | £105 |
| CEF32, Epstein – Barr Virus latent NA – 3C (281 – 290) | EENLLDFVRF | AB-CEF032 | 1 mg | £105 |
| CEF33, Cytomegalovirus, HCMV pp65 | EFFWDANDIY | AB-CEF033 | 1 mg | £105 |
Related articles
Influenza virus peptides
Although there are ways to combat influenza viruses, they have evolved to mutate frequently in order to evade the host’s immune system.
Protein and peptide tags
Protein and peptide (epitope) tag sequences are attached to proteins to facilitate easy detection and purification of expressed proteins.
Peptides for Raising Antibodies
In this article, we discuss methods for generating custom antibodies using peptide antigens including peptide antigen design considerations and options for generating antigenic peptides. In general, synthetic peptides are too small to elicit an immunogenic response.